INTRODUCTION

Until now, the glomerular filtration rate (GFR) was considered the best overall method of estimating the renal function of subjects (1). The determination of urinary clearance of exogenous substances, such as inulin, $^{99m}$Tc-DTPA, and $^{51}$Cr-EDTA, has traditionally been considered the ideal standard method for estimating accurate GFR (2). Even though methods using exogenous substances are accurate, these procedures cannot be easily applied in clinical practice because of the need for continuous exogenous substance infusions, frequent urine samplings, and high cost. To overcome these limitations, formulas to estimate or predict 'true GFR' using serum creatinine levels were developed. Two commonly used representative formulas for the assessment of GFR in adults are the Modification of Diet in Renal Disease Study (MDRD) equation (3) and the Cockroft-Gault (C&G) equation (4). Cystatin C is a member of the family of cysteine protease inhibitors. It has a low molecular weight of only 13 kDa and is produced by all nucleated cells at a stable rate. Cystatin C was first discovered as a promising endogenous marker for GFR in 1985 (5, 6). It is wholly filtered through the glomerulus and then reabsorbed, being successively metabolized without secretion in the proximal tubule. Dharnidharka et al. (7) performed a meta-analysis of 46 cystatin C-related studies to evaluate the superiority of cystatin C levels over serum creatinine. These authors determined that serum cystatin C is a more potent marker of GFR than serum creatinine. Recently, Herget-Rosenthal and his colleagues found that determining cystatin C levels is a more sensitive test for the early detection of renal function impairment or reduced GFR (1). It has been recognized that an increase in serum cystatin C might well reflect changes in renal function or GFR for renal injury in diverse clinical conditions or diseases, including nephropathy associated with type 2 diabetes mellitus (8), hypertensive nephropathy (9), solid organ transplantation...
Cystatin C as a Marker for Renal Function in Gout Patients

Gout is an inflammatory rheumatic disease characterized by deposition of crystallized monosodium urate, and uric acid, within the joints. It is frequently associated with hyperuricemia (12). The spectrum of renal diseases in gout patients includes urate stones, acute uric acid nephropathy, and chronic urate nephropathy. Chronic urate nephropathy may be associated with a series of complicating factors, such as hormonal changes, insulin resistance, therapeutic drug management for gout, and microvascular damage from untreated hypertension, rather than simply from excessive depositions of uric acid within renal tissues. Whatever the underlying mechanism of renal disease in gout patients, individuals with gout have renal problems. 

Currently, there are no clinical studies regarding the potential of using serum cystatin C to predict renal impairment in gout patients. Therefore, our study was designed 1) to compare diagnostic accuracy between serum cystatin C and serum creatinine and 2) to identify non-renal determinants associated with serum cystatin C in patients with gout.

MATERIALS AND METHODS

Subjects

For this study, 68 male Korean gout patients with renal impairment from the outpatient clinic of the Department of Rheumatology at Daegu Catholic University Medical Center were enrolled who fulfilled the preliminary criteria for the classification of primary gout put forth by the American College of Rheumatology (13). Patients who participated in this study gave informed consent for review of their medical records and use of urine and blood samples. This study was approved by the Institutional Review Board Committee of the Daegu Catholic University Medical Center.

Exclusion criteria were as follows; patients on dialysis treatment, those with chronic renal disease at either stage IV or V according to guidelines proposed by the National Kidney Foundation of the United States through its Kidney Disease Outcomes Quality Initiative (K/DOQI) program (14), and individuals with diabetic nephropathy or hypertensive nephropathy. Based on the K/DOQI guidelines, patients enrolled in this study were assigned to one of three groups; normal GFR (≥90 mL/min/1.73 m² and persistent albuminuria; stage 1 of chronic kidney disease [CKD]), mildly decreased GFR (60-89 mL/min/1.73 m² and persistent albuminuria; stage 2 of CKD), and moderately decreased GFR (30-59 mL/min/1.73 m²; stage 3 of CKD).

Methods

Blood was sampled from a forearm vein after midnight fasting of 12-hr and stored at -70℃ until laboratory tests were performed. And spot urine collection was simultaneously acquired. Twenty four-hours urine collection was performed before the visit to the outpatient clinic for 1 day. Body mass index (BMI, kg/m²) was assessed. Disease duration in patients was estimated by examining medical records and interviewing individual patients.

Serum creatinine, serum cystatin C, blood urea nitrogen, serum uric acid, fasting glucose, lipid profiles such as total cholesterol, high density lipoprotein cholesterol (HDL-cholesterol), low density lipoprotein cholesterol (LDL-cholesterol), and triglyceride, erythrocyte sediment rate (ESR), and C-reactive protein (CRP) were assessed from blood samples at the time of enrollment in this study. Serum creatinine concentration was determined by the kinetic Jaffe method according to the manufacturer’s instructions (Cobas Integra, Roche, Switzerland). The quantitative measurement of cystatin C in human serum was performed using the HiSense latex-enhanced turbidimetric immunoassay cystatin C kit (HBI Co, Anyang, Korea). The degree of agglutination between latex particles coated with antibodies specific for human cystatin C and serum cystatin C levels is closely correlated with the concentration of cystatin C in the sample. An optical density reading at 660 nm of the aggregates was used to calculate the concentration of serum cystatin C.

GFR was estimated from creatinine clearance (Ccr) using a 24-hr urine collection in the subjects. The propriety of the urine collection was referred from the guideline that daily creatinine excretion should be 20 to 25 mg/kg of lean body weight in male adults. Estimates of GFR were corrected for a body surface area of 1.73 m² using the method of DuBois and DuBois. Ccr was used as the reference GFR to assess the diagnostic efficacy of the test.

Statistic analysis

The data are presented as mean ± standard deviation (SD) or number (n) and proportion (%). The differences in continuous variables among the three stages of renal function were compared by ANOVA test. Linear correlations were verified using the Pearson correlation test between continuous variables or using Spearman’s correlation analysis between continuous and non-continuous variables. After simple linear regression analysis, confounding factors related to serum cystatin C concentration were reanalyzed using multivariate regression analysis.

Non-parametric receiver operating characteristic (ROC) analyses were performed to evaluate diagnostic values of individual parameters generated by graphically plotting sensitivity versus 1-specificity. The diagnostic accuracy of the test is measured by the area under the curve (AUC). Statistical significance is considered a value of P < 0.05. All statistical analyses were performed using SPSS version 12.0 software (SPSS Inc., Chicago, IL, USA).
RESULTS

Basic clinical characteristics of enrolled patients

A total of 68 male gouty patients with renal impairment (54.6 ± 11.5 yr of mean age and 6.4 ± 5.6 yr of mean disease duration) were enrolled in this study. Clinical parameters related to the characteristics of patients and renal function were assessed; these included age at study, disease duration, body mass index (BMI), serum uric acid, uses of medications for gout such as colchicine, allopurinol, benzbromarone, and non-steroidal anti-inflammatory drugs (NSAIDs), lipid profiles, fasting glucose, ESR, CRP, serum cystatin C levels, serum creatinine levels, and Ccr (Table 1). In this study, we assigned enrolled patients to one of three groups; 28 patients were in the stage 1 of CKD, 22 patients in stage 2 of CKD, and 18 patients in stage 3 of CKD.

The differences in clinical parameters between the three groups were analyzed by ANOVA test. The results showed significant differences in age at study (49.1 ± 10.6 vs. 56.1 ± 9.7 vs. 61.1 ± 11.3, P < 0.001), serum cystatin C (0.9 ± 0.2 vs. 1.1 ± 0.2 vs. 1.4 ± 0.4, P < 0.001), serum creatinine (1.0 ± 0.2 vs. 1.1 ± 0.2 vs. 1.4 ± 0.3, P < 0.001), and blood urea nitrogen (17.2 ± 5.9 vs. 15.5 ± 4.3 vs. 22.1 ± 5.8, P < 0.001) among three groups. However, clinical parameters such as disease duration, BMI, serum uric acid, total cholesterol, HDL-cholesterol, LDL-cholesterol, triglyceride, fasting glucose, CRP, and ESR did not reveal significant differences among the three groups (data not shown).

Association of serum cystatin C and serum creatinine for GFR with Ccr

The measured renal parameters, both serum cystatin C and serum creatinine, were significantly correlated with GFR of Ccr (Fig. 1). The correlation coefficient between 1/cystatin C and Ccr (r = 0.702, P < 0.001) was higher than that between 1/creatinine (r = 0.665, P < 0.001) and Ccr (Fig. 1). A significant correlation between serum creatinine and serum cystatin C was also identified (r = 0.815, P < 0.001).

Clinical and laboratory parameters related with serum cystatin C

We also identified non-renal determinants associated with serum cystatin C in this study using simple linear correlation analysis. Among all patients, serum cystatin C was closely related with stages of renal function (r = 0.576, P < 0.001), age

Table 1. Characteristics of clinical and biochemical parameters in gout patients with renal impairment (n=68)

| Clinical and biochemical parameters | Mean±SD |
|-------------------------------------|---------|
| Age (yr)                            | 54.6±11.5 |
| Disease duration (yr)               | 6.4±5.6  |
| BMI (kg/m²)                         | 25.2±2.7 |
| Serum cystatin C (mg/L)             | 1.1±0.34 |
| Blood urea nitrogen (mg/dL)         | 18.0±6.0 |
| Serum creatinine (mg/dL)            | 1.1±0.30 |
| Creatinine clearance (mL/min/1.73 m²)| 88.9±36.4 |
| Serum uric acid (mg/dL)             | 5.7±2.1  |
| Total cholesterol (mg/dL)           | 189.0±36.0 |
| HDL-cholesterol (mg/dL)             | 49.5±13.9 |
| LDL-cholesterol (mg/dL)             | 121.6±31.9 |
| Triglyceride (mg/dL)                | 172.8±86.3 |
| Fasting glucose (mg/dL)             | 98.2±19.5 |
| C-reactive protein (mg/dL)          | 2.6±4.1  |
| Erythrocyte sediment reaction (mm/hr)| 9.1±7.6  |
| Medical therapy, No. (%)            |         |
| Colchicines                          | 63 (92.6) |
| Allopurinol                          | 38 (55.9) |
| Benzbromarone                        | 32 (47.1) |
| NSAIDs                               | 58 (85.3) |
| Renal functional status*, No. (%)   |         |
| Stage 1                              | 28 (41.2) |
| Stage 2                              | 22 (32.3) |
| Stage 3                              | 18 (26.5) |

*Estimated according to K/DOQI guideline.
SD, standard deviation; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein; NSAID, non-steroidal anti-inflammatory drugs; GFR, glomerular filtration rate; Ccr, Creatinine clearance.

Fig. 1. Correlation between the 1/serum cystatin C and 1/serum creatinine for GFR estimated by Ccr.
at study (r=0.586, P<0.001), the use of allopurinol (r=0.406, P=0.001), the use of benzbromarone (r=-0.329, P=0.006), serum uric acid (r=0.379, P=0.001), ESR (r=0.364, P=0.002), CRP (r=0.279, P=0.021), and HDL-cholesterol (r=-0.265, P=0.033). Multivariate regression analysis identified that more advanced renal stage (B=0.140, P=0.001), older age (B=0.011, P=0.005), use of allopurinol (B=-0.218, P=0.007), and lower HDL-cholesterol (B=-0.005, P=0.015) were associated with higher serum cystatin C in gout patients (Table 2).

Correlation for clinical and biochemical parameters according to renal function was assessed in each three groups. Some clinical parameters, such as the use of allopurinol (r=0.447, P=0.017), serum uric acid (r=0.419, P=0.027), and CRP (r=0.477, P=0.010) for stage 1 of CKD, only age at study (r=0.530, P=0.011) for stage 2, and age at study (r=0.517, P=0.028), the use of allopurinol (r=0.497, P=0.036), BUN (r=0.474, P=0.047), and ESR (r=0.677, P=0.002) were significantly associated with serum cystatin C. However, Multivariate regression analysis for each renal function group showed only age of study was significantly correlated with serum cystatin C at both stage 2 and stage 3 of CKD (P=0.011 and P=0.018, respectively), although parameters related with serum cystatin C could not be identified.

Diagnosis accuracy of serum cystatin C in gout

The diagnostic accuracy of serum cystatin C was evaluated using a non-parametric ROC plot (Fig. 2). The results showed that the AUC for serum cystatin C had greater areas compared with that of serum creatinine (AUC 0.804, P<0.001 vs. AUC 0.745, P=0.001). This findings demonstrated serum cystatin C in gout patients has more diagnostic accuracy compared with serum creatinine.

DISCUSSION

Serum cystatin C has been recognized as a reliable endogenous index of GFR, since its introduction in 1985 (5, 6). In addition, more sensitive indicators of GFR or renal function have been identified in a variety of diverse systemic diseases including nephropathy in type 2 diabetes mellitus (8), hypertensive nephropathy (9), solid organ transplantation (10), and coronary angiopathy (11). Few studies have investigated serum cystatin C as an endogenous marker of renal function in rheumatic diseases other than rheumatoid arthritis (15, 16). This is the first study to investigate the clinical application of serum cystatin C to assess renal function in gout patients with renal impairment. We found that serum cystatin C is closely associated with serum creatinine and a good potential marker of GFR in gout patients.

Gout is a common, manageable medical disease related to other systemic rheumatic diseases and has a wide spectrum of clinical features, ranging from acute gouty arthritis to chronic tophaceous gout. This disease is frequently associated with hyperuricemia (defined as a serum urate concentration over 7 mg/dL) due to overproduction or underexcretion of urate, or a combination of both. The physician should pay careful attention to the development of associated comorbidities, such as chronic renal diseases, cardiovascular diseases, or metabolic syndrome. Of special clinical interest is the association between gout and chronic renal diseases. However, some debate remains as to whether impairment of renal function is related to complicating factors such as hormonal changes, insulin resistance, therapeutic drugs, and untreated hypertension, or to excessive depositions within renal tissue leading to renal impairment, cell death and tissue hypoxia by hyperuricemia (17). Talbott and Terplan (18) presented diverse histopathological findings in the biopsies and autopsy from 279 gout patients, and identified both clinicolaboratory and pathologic findings. Murray and Goldberg (19) showed that hyperuricemia was a primary cause of chronic interstitial ne-
phritis in a retrospective study of 101 patients. Recent study
determined that hyperuricemia may contribute to the de-
velopment of chronic gouty nephropathy as well as play a cru-
ded role in the progression of renal pathology (17).

Until now, traditional measures for assessing renal function
such as measuring serum creatinine have been widely used
in gout patients, although they have some limitations for
accurate estimation of GFR. Here, we evaluated the diagno-
sitic efficacy and accuracy of using serum cystatin C levels
to estimate GFR and compared these results to those obtained
using traditional renal function indicators such as serum cre-
atinine and Ccr. Analysis for linear associations showed that
reciprocal cystatin C levels correlate well with Ccr of 24 hr
urine (r=0.702). In addition, the level of cystatin C is better
correlated with Ccr than the reciprocal creatinine level (r=
0.665) (Fig. 1). Our results from 68 male gout patients indi-
cate that serum cystatin C is a novel and reliable marker of
GFR. Zahran et al. (20) reviewed a number of studies to com-
pare the diagnostic accuracy of serum cystatin C levels and
serum creatinine levels in many clinical situations, includ-
ing transplant patients, patients with native kidney disease,
adults with native kidney disease, and pediatric patients with
native kidney disease (20). Their finding that serum cystatin
C was superior to serum creatinine remains controversial;
many investigators prefer to use serum cystatin C rather than
serum creatinine as an index of GFR (1, 7, 20). Our study
found that the diagnostic accuracy of serum cystatin C levels
were superior to that of serum creatinine using a ROC curve.

The weaknesses of traditional measures of GFR including
serum creatinine have been recognized (1). Although serum
creatinine has become the most popularly used serum marker
of renal function, serum creatinine may be unreliable because
they are frequently affected by muscle mass, age, gender, and
aberrant renal tubular regulation of serum creatinine result-
ing in an overestimation of GFR. Using serum cystatin C
levels has some advantages over serum creatinine and creat-
inine-based calculated GFR formulas, in that serum cystatin
C levels are independent of age, gender, muscle mass, and
renal tubular secretion (1). Tenstad et al. (21) found that the
renal plasma clearance of cystatin C correlated well with GFR
using 51Cr-EDTA with a linear correlation coefficient of 0.99.
Given these characteristics, cystatin C can be considered to
be an ideal indicator of GFR. The present study also found
that serum cystatin C showed a good inverse correlation to
Ccr in gout patients (r=0.702, P<0.001).

It has long been known that cystatin C levels are not highly
influenced by confounding factors, such as diet, nutrition, or
inflammatory status, whereas measurements for GFR based
on creatinine levels, including the MDRD or C&G formu-
las, have substantial limitations such as age, sex, muscle mass,
etnicity, and methodology of determining serum creatinine
level (1) However, cystatin C production was not thought to
be affected by any factors until several authors demonstrated
that serum cystatin C could be affected by both rheumatoid
factor (22) and high doses of glucocorticoid (23). Addition-
ally, indirect evidence, including decreasing cystatin C in asth-
matic patients after cyclosporine therapy (24) and the pos-
tive correlation between CRP and cystatin C levels in large
populations indicates that inflammatory status may also con-
tribute to changes in serum cystatin C levels (25). In the pre-
sent study, we assessed whether certain demographic and clini-
cal factors were correlated with serum cystatin C levels among
all enrolled patients. The data from our analyses indicates
that the stage of renal disease, the age of patients at the time
of study, serum uric acid, and HDL-cholesterol all influence
the serum cystatin C level. In addition, allopurinol-treated
patients have a tendency to have higher serum cystatin C lev-
els. It may be considered that gout patients with renal impair-
ment have allopurinol rather than benzbromarone as a uric
acid lowering agent. Interestingly, our data illustrated a weakly
positive association between ESR and serum cystatin C levels.

This finding suggests that serum cystatin C can be influenced
by inflammatory changes, which is in agreement with results
of some previous studies (24, 25), but in contrast to the data
of others (15). These conflicting results necessitate further
investigation into the effects of acute phase reactants such as
ESR and CRP on changes in the levels of serum cystatin C.
In addition, only age at study was significantly correlated
with serum cystatin C at subgroup analysis according to renal
function status. This discrepancy between whole enrolled
patients and each group patients may be resulted from small-
sized populations.

Our study evaluated the diagnostic performance of serum
cystatin C using Ccr as a reference GFR, even though the limi-
tations of this technique were highlighted in previous stud-
ies (26, 27). However, Herget-Rosenthal et al. (28) discussed
creatinine clearance for GFR as an equivalent marker of true
GFR, likening it to different “gold standard” methods of GFR
including inulin, 125I-iothalamate, and 99mTc-DTPA. In their
study, cystatin C was found to be an accurate index of GFR
in 110 renal transplantation patients. Several studies regard-
ing cystatin C as diagnostic index of renal function in renal
transplant patients using Ccr as a reference GFR have been
performed, although the accuracy of serum cystatin C and
serum creatinine for evaluating GFR differed between the
various studies (28). Finally, some studies have demonstrat-
ed similar diagnostic performances of serum cystatin C and
serum creatinine levels using different GFR references such
as inulin (29) and 51Cr-EDTA (30).

Data derived from our cross-sectional study in 68 male gout
patients with renal impairment illustrates that the serum
cystatin C level is a novel and reliable marker for accurately
predicting GFR that is superior to serum creatinine. This is
the first study to demonstrate the clinical application of serum
cystatin C levels in the field of gout, one of the inflammato-
ry rheumatic diseases. In addition to renal parameters in gout
patients, the results of this study revealed an association be-
 tween non-renal components such as allopurinol use and HDL-
cholersterol level and serum cystatin C. In the realm of inflammatory rheumatic diseases such as rheumatoid arthritis and gout, renal issues are continuous and prominent. There are some limitations for this study. The characteristics or patterns of changes of serum cystatin C level were not observed in this study because of limitation of cross-sectional study. And this study could not reveal relationship between serum cystatin C and inflammatory status of acute or interval stage of gout or serologic markers, such as CRP, ESR, or serum amyloid. To overcome these limitations, well-designed longitudinal study for serum cystatin C will be necessary in larger population.

In conclusion, serum cystatin C is a reliable endogenous marker for detection of renal impairment and estimation of true GFR. To conclusively determine the diagnostic value of serum cystatin C levels for monitoring renal function of gouty patients, further prospective studies in a larger study population are needed.

REFERENCES

1. Herget-Rosenthal S, Bökенkamp A, Hofmann W. How to estimate GFR-serum creatinine, serum cystatin C or equations? Clin Biochem 2007; 40: 153-61.
2. Perrone RD, Steinman TI, Beck GJ, Skibinski CI, Royal HD, Lawlor M, Hunsicker LG. Utility of radiotopic filtration markers in chronic renal insufficiency: simultaneous comparison of 125I-iothalamate, 113Yb-DTPA, 99mTc-DTPA, and insulin. The Modification of Diet in Renal Disease Study. Am J Kidney Dis 1990; 16: 224-35.
3. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999; 130: 461-70.
4. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
5. Grubb A, Simonsen O, Sturfelt G, Truedsson L, Thysell H. Serum concentration of cystatin C, factor D and beta 2-microglobulin as a measure of glomerular filtration rate. Acta Med Scand 1985; 218: 499-503.
6. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gammatrace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985; 45: 97-101.
7. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40: 221-6.
8. Mussap M, Dalla Vestra M, Fioretto P, Saller A, Varagnolo M, Nosadini R, Plebani M. Cystatin C is a more sensitive marker than creatinine for the estimation of GFR in type 2 diabetic patients. Kidney Int 2002; 60: 1453-61.
9. Ozer BA, Dursun B, Baykal A, Gultekin M, Suleymanlar G. Can cystatin C be a better marker for the early detection of renal damage in primary hypertensive patients? Ren Fail 2005; 27: 247-53.
10. Ling Q, Xu X, Li J, Wu J, Chen J, Xie H, Zheng S. A new serum cystatin C-based equation for assessing glomerular filtration rate in liver transplantation. Clin Chem Lab Med 2008; 46: 405-10.
11. Artunc FH, Fischer IU, Risler T, Erley CM. Improved estimation of GFR by serum cystatin C in patients undergoing cardiac catheterization. Int J Cardiol 2005; 102: 173-8.
12. Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med 2005; 143: 499-516.
13. Wallace SL, Robinson H, Masi AT, Decker JL, McCarty DJ, Yu TF. Preliminary criteria for the classification of the acute arthritis of primary gout. Arthritis Rheum 1977; 20: 895-900.
14. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39 (2 Suppl 2): S1-266.
15. Karstila K, Harmoinen AP, Lehtimäki TJ, Korpela MM, Mustonen JT, Saha HH. Measurement of the kidney function in patients with rheumatoid arthritis: plasma cystatin C versus 51Cr-EDTA clearance. Nephron Clin Pract 2008; 108: e284-90.
16. Bokarewa M, Abrahamsson M, Levshin N, Eggesten A, Grubb A, Dahlberg L, Tarkowski A. Cystatin C binds serum amyloid A, downregulating its cytokine-generating properties. J Rheumatol 2007; 34: 1293-301.
17. Kang DH, Nakagawa T. Uric acid and chronic renal disease: possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005; 25: 43-9.
18. Talbott JH, Terplan KL. The kidney in gout. Medicine (Baltimore) 1960; 39: 405-67.
19. Murray T, Goldberg M. Chronic interstitial nephritis, Etiologic factors. Ann Intern Med 1967; 82: 453-9.
20. Zahran A, El-Husseini A, Shoker A. Can cystatin C replace creatinine to estimate glomerular filtration rate? A literature review. Am J Nephrol 2007; 27: 197-205.
21. Tenstad O, Roald AB, Grubb A, Aukland K. Renal handling of radiolabelled human cystatin C in the rat. Scand J Clin Lab Invest 1996; 56: 409-14.
22. Lamb E, Stowe H. Rheumatoid factor can interfere with cystatin C measurement. Ann Clin Biochem 2003; 40: 195-6.
23. Risch L, Horklotz R, Blumberg A, Huber AR. Effects of glucocorticoid immunosuppression on serum cystatin C concentrations in renal transplant patients. Clin Chem 2001; 47: 2055-9.
24. Cimerman N, Briguljan PM, Krasovec M, Suskovic S, Kos J. Serum cystatin C, a potent inhibitor of cysteine proteinases, is elevated in asthmatic patients. Clin Chim Acta 2000; 300: 83-95.
25. Knight EL, Verhave JC, Spiegelman D, Hillege HL, de Zeeuw D, Curhan GC, de Jong PE. Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement. Kidney Int 2004; 65: 1416-21.
26. Toto RD. Conventional measurement of renal function utilizing serum creatinine, creatinine clearance, insulin and para-aminohippuric acid clearance. Curr Opin Nephrol Hypertens 1995; 4: 505-9.
27. Shemesh O, Golbetz H, Kriss JP, Myers BD. Limitations of creatinine as a filtration marker in glomerulopathic patients. Kidney Int 1985; 28: 830-8.
28. Herget-Rosenthal S, Trabold S, Huesing J, Heemann U, Philipp T, Kribben A. Cystatin C-an accurate marker of glomerular filtration
rate after renal transplantation? Transpl Int 2000; 13: 285-9.

29. Schück O, Teplan V, Jabor A, Stollova M, Skibova J. Glomerular filtration rate estimation in patients with advanced chronic renal insufficiency based on serum cystatin C levels. Nephron Clin Pract 2003; 93: c146-51.

30. Donadio C, Lucchesi A, Ardini M, Giordani R. Cystatin C, beta 2-microglobulin, and retinol-binding protein as indicators of glomerular filtration rate: comparison with plasma creatinine. J Pharm Biomed Anal 2001; 24: 835-42.